CTTQ Pharma

CTTQ Pharma, a core subsidiary of Sino Biopharmaceutical, is a leading Chinese pharmaceutical company specializing in the research, development, and manufacturing of innovative drugs. The company is widely recognized as a dominant player in the Chinese hepatology market, particularly for its treatments for Hepatitis B. Beyond liver disease, CTTQ has aggressively expanded into oncology, respiratory, and cardiovascular therapeutic areas, with its flagship multi-target kinase inhibitor, Anlotinib, achieving significant commercial success. The company maintains a robust R&D infrastructure with centers in Lianyungang and Nanjing, focusing on both small molecules and biologics. CTTQ frequently engages in strategic partnerships with global biotech firms to in-license innovative therapies for the Chinese market.